316 related articles for article (PubMed ID: 21701624)
1. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.
Dalle Carbonare L; Zanatta M; Gasparetto A; Valenti MT
Drug Healthc Patient Saf; 2010; 2():121-37. PubMed ID: 21701624
[TBL] [Abstract][Full Text] [Related]
2. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates.
Cosman F
Endocr Pract; 2009; 15(5):483-93. PubMed ID: 19491081
[TBL] [Abstract][Full Text] [Related]
3. Injectable bisphosphonates for the treatment of osteoporosis.
Reginster JY; Burlet N; Close P; Bruyere O
Womens Health (Lond); 2007 Nov; 3(6):719-23. PubMed ID: 19803981
[TBL] [Abstract][Full Text] [Related]
4. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
5. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
6. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
7. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
Dalle Carbonare L; Bertoldo F; Lo Cascio V
Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
[TBL] [Abstract][Full Text] [Related]
8. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
9. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
Moro-Alvarez MJ; Díaz-Curiel M
Clin Interv Aging; 2008; 3(2):227-32. PubMed ID: 18686745
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Jeffery TC; Chang AB; Conwell LS
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD002010. PubMed ID: 36625789
[TBL] [Abstract][Full Text] [Related]
11. Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.
Adami S; Idolazzi L; Rossini M
Ther Adv Musculoskelet Dis; 2011 Apr; 3(2):67-79. PubMed ID: 22870467
[TBL] [Abstract][Full Text] [Related]
12. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD; Delmas PD
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
Zhou J; Ma X; Wang T; Zhai S
Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
[TBL] [Abstract][Full Text] [Related]
14. Long-term use of bisphosphonates in osteoporosis.
Watts NB; Diab DL
J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
[TBL] [Abstract][Full Text] [Related]
15. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
16. Differences between the bisphosphonates for the prevention and treatment of osteoporosis.
Grey A; Reid IR
Ther Clin Risk Manag; 2006 Mar; 2(1):77-86. PubMed ID: 18360583
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
18. Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis.
Boonen S; Eastell R; Su G; Mesenbrink P; Cosman F; Cauley JA; Reid IR; Claessens F; Vanderschueren D; Lyles KW; Black DM
J Bone Miner Res; 2012 Jul; 27(7):1487-93. PubMed ID: 22431413
[TBL] [Abstract][Full Text] [Related]
19. Use of intravenous bisphosphonates in osteoporosis.
Civitelli R; Napoli N; Armamento-Villareal R
Curr Osteoporos Rep; 2007 Mar; 5(1):8-13. PubMed ID: 17320022
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the antifracture efficacy of bisphosphonates.
Pazianas M; Epstein S; Zaidi M
Rev Recent Clin Trials; 2009 May; 4(2):122-30. PubMed ID: 19463108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
